The Prevention Theorem: Time-Dependent Constraints on Post-Exposure Prophylaxis for HIV

A.C. Demidont, DO[a,b,*]

[a]*Independent Researcher*
[b]*Nyx Dynamics, LLC, 268 Post Rd. East, Fairfield, CT 06428, USA*

Abstract

Antiretroviral agents for HIV prevention are typically evaluated in terms of trial efficacy and programmatic coverage, but rarely in terms of whether they admit a true mathematical solution to prevention. Here we introduce the Prevention Theorem, which formalizes prevention for a given exposure e as the condition $R_0(e) = 0$, meaning that the probability of establishing a productive, transmissible infection is exactly zero. Within this framework, post-exposure prophylaxis (PEP) is not delayed treatment but a time-dependent operator acting on within-host infection establishment dynamics. Using a mechanistic model of reservoir seeding and proviral integration, we derive the PEP Window Corollary: PEP can enforce $R_0(e) = 0$ only when initiated within a finite biological window prior to irreversible integration and initial reservoir establishment. Beyond this window, all reachable system states satisfy $R_0(e) > 0$ and are irreducible by post-exposure intervention. Parameterization using virological data indicates that this window extends to approximately 72 hours for mucosal exposures but is compressed to roughly 12–24 hours for parenteral exposures due to bypass of early immune bottlenecks. As an applied example, we show that structural access delays in high-risk populations—such as people who inject drugs—frequently exceed this compressed parenteral window. Consequently, for such exposures the condition $R_0(e) = 0$ is mathematically and biologically unreachable before access is even attempted, rendering the failure of post-exposure prevention a consequence of violated biological boundary conditions rather than pharmacological efficacy.

Keywords: HIV prevention, Mathematical modeling, Prevention Theorem, PEP timing,

*Corresponding author
Email address: ac.demidont@nyxdynamics.com (A.C. Demidont, DO)

Highlights

- Prevention is defined mathematically as the condition $R_0(e) = 0$.

- PEP operates as a time-dependent function racing against irreversible integration.

- A finite biological window exists beyond which prevention is mathematically impossible.

- Parenteral exposures compress this window to 12–24 hours, bypassing mucosal bottlenecks.

- Structural access delays in PWID invariably exceed this compressed biological limit.

1. Introduction

Despite the availability of antiretroviral agents with trial efficacies approaching or exceeding 99%, HIV prevention following exposure remains constrained by the biological dynamics of infection establishment [1, 2]. Prevention is often discussed as a matter of coverage, adherence, or early treatment, implicitly assuming that post-exposure intervention remains feasible at all times following contact. A formal evaluation of this assumption requires specifying what prevention means in mathematical terms. Previous work has shown that HIV transmission and progression models are often highly sensitive to uncertain biological parameters, underscoring the difficulty of drawing robust conclusions from long-horizon simulations without strong constraints on initial conditions and system dynamics[3].

We define prevention for a specific viral exposure e as the condition $R_0(e) = 0$, corresponding to zero probability that the exposure establishes a productive, transmissible infection. Any state satisfying $R_0(e) > 0$ admits non-zero onward transmission and therefore cannot be considered complete prevention. Within this formulation, pre-exposure prophylaxis enforces $R_0(e) = 0$ by rendering the host non-susceptible prior to contact, whereas post-exposure prophylaxis (PEP) attempts to enforce $R_0(e) = 0$ after contact but before infection establishment becomes irreversible.

Crucially, PEP operates as a time-dependent operator acting on within-host establishment dynamics, racing against irreversible biological processes including proviral integration and latent reservoir seeding. Once these processes are complete, the system undergoes a phase transition to an irreducible infection state in which $R_0(e) > 0$ is permanently fixed, independent of subsequent therapeutic intervention [4, 5, 6]. This formulation applies to any pathogen in which irreversible genomic integration or long-lived latent reservoirs fix infection status beyond a critical temporal threshold.

In the sections that follow, we formalize this constraint through the Prevention Theorem and its corollaries, derive the finite temporal window during which PEP can enforce prevention, and illustrate the consequences of violating this boundary condition using the structural context of injection drug use as an applied example.

2. Methods

2.1. Theoretical Framework: The Prevention Theorem

We define the state of true prevention for a specific viral exposure e as the condition where the basic reproductive number for that exposure, $R_0(e)$, is exactly zero.

$$\text{Condition for Prevention: } R_0(e) = 0 \tag{1}$$

This condition implies that the probability of the exposure establishing a productive, transmissible infection is zero [7, 8]. Interventions are classified by their ability to enforce this condition. Pre-exposure prophylaxis (PrEP) enforces $R_0(e) = 0$ by rendering the host non-susceptible prior to contact. Post-exposure prophylaxis (PEP) attempts to enforce $R_0(e) = 0$ by extinguishing the virus after contact but before the infection becomes self-sustaining.

2.2. Closed-Form Prevention Solution

Let $R(t)$ denote the total number of infected cells resulting from a single exposure event at time t. The system admits exactly one closed-form prevention solution:

$$R(0) = 0 \implies R(t) = 0 \quad \forall t. \tag{2}$$

3

If no infected cells exist at the initial condition, no infected cells can arise at any future time. For any initial condition satisfying $R(0) > 0$, no post-exposure or therapeutic intervention can mathematically guarantee $R(t) = 0$; all such interventions act only on the subsequent trajectory of $R(t)$ and not on its initial condition [9].

2.3. Infection Establishment Dynamics

We model within-host establishment dynamics following a single exposure event using logistic formulations for reservoir seeding, $P_{\text{seed}}(t)$, and proviral integration, $P_{\text{int}}(t)$ [4]. These functions describe the cumulative probability that irreversible biological transitions have occurred by time t.

2.4. Master Equation for Time-Dependent Prevention

The efficacy of post-exposure intervention is time-dependent. We define the reproductive number as a function of intervention timing:

$$R_0(e, t) = 1 - E_{\text{PEP}}(t) \tag{3}$$

with the efficacy function defined as:

$$E_{\text{PEP}}(t) = (1 - P_{\text{seed}}(t))\,\varepsilon_{\text{max}} + (P_{\text{seed}}(t) - P_{\text{int}}(t))\,\varepsilon_{\text{mid}} + P_{\text{int}}(t)\,\varepsilon_{\text{min}} \tag{4}$$

Here, ε_{max} represents efficacy prior to seeding, ε_{mid} represents efficacy during the seeding window, and ε_{min} represents efficacy after integration is established (typically zero for prevention purposes).

Because $E_{\text{PEP}}(t)$ depends on cumulative probabilities of irreversible biological transitions, once integration is established, this operator, $E_{\text{PEP}}(t) \to 0$ and $R_0(e, t)$, admits a hard temporal cutoff once established.[10]

Corollary 1 (PEP Window Corollary): *Post-exposure prophylaxis can enforce the prevention condition $R_0(e) = 0$ if and only if initiated within a finite biological window $t < t_{crit}$ prior to irreversible proviral integration. Beyond this critical threshold, all reachable system states satisfy $R_0(e) > 0$ and are irreducible by post-exposure intervention or any therapeutic option currently available.*

3. Results

3.1. Visualization of the Theorem

Figure 1 illustrates the four core components of the Prevention Theorem. Panel A shows the timeline of infection establishment, with reservoir seeding preceding proviral integration. Panel B demonstrates the time-dependent efficacy function $E_{\text{PEP}}(t)$, which decays monotonically toward zero as irreversible transitions accumulate. Panel C visualizes the phase transition into the irreducible infection state, where the probability of infection approaches certainty. Panel D summarizes the mathematical formalism.

Figure 1: **The Prevention Theorem: Dynamics of Infection Establishment and Post-Exposure Prevention.** Panel A shows cumulative probabilities of reservoir seeding (dashed blue) and proviral integration (solid red) over time. Panel B displays the time-dependent efficacy function $E_{\text{PEP}}(t)$, which decays as integration progresses. Panel C illustrates the transition from preventable to irreducible states, with the green zone representing the window during which $R_0(e) = 0$ is achievable and the red zone representing the irreducible infection state. Panel D restates the theorem: prevention requires $R_0(e) = 0$, which is only achievable while $P_{\text{int}}(t) < 1$.

5

3.2. Finite Prevention Window for Post-Exposure Prophylaxis

Model parameterization indicates that the window for enforcing $R_0(e) = 0$ extends to approximately 72 hours for mucosal exposures, constrained by local immune bottlenecks [10]. However, for parenteral exposures (e.g., injection), this window is compressed to roughly 12–24 hours due to the bypass of early mucosal barriers and rapid systemic dissemination [11]. This "left-shift" of the critical window significantly reduces the timeframe for effective intervention.

Figure 2 demonstrates the quantitative compression of the prevention window between mucosal and parenteral exposures. The parenteral route (red dashed line) shows a precipitous decline in prevention efficacy within the first 24 hours, whereas the mucosal route (blue solid line) maintains higher efficacy through 72 hours. This differential is driven by the distinct immunological bottlenecks encountered in each tissue compartment.


Figure 2: **Compression of the Prevention Window for Parenteral Exposure.** The solid blue line shows the probability of prevention success following mucosal exposure, which remains effective through approximately 72 hours. The dashed red line shows the dramatically compressed window for parenteral exposure, with prevention efficacy approaching zero by 24 hours. The differential reflects the bypass of mucosal immune barriers in systemic exposures, allowing more rapid establishment of productive infection.

3.3. Irreducible Infection State

Proviral integration represents a thermodynamically irreversible transformation of the host genome. Once integrated, viral DNA persists for the lifetime of the cell and is propagated to all daughter cells during division, producing clonal expansion independent of ongoing viral replication [5].

$$G(t+1) = G(t) + \mathrm{HIV}_{\mathrm{provirus}} \tag{5}$$

No biologically realizable inverse transformation exists that restores the pre-integration genomic state. Consequently, once integration occurs, the condition $R_0(e) = 0$ is mathematically unattainable [12, 13].

3.4. Reservoir Stratification

Long-lived viral reservoirs persist in specific cellular compartments, including naïve T-cells, central memory T-cells (T_{CM}), stem cell-like memory T-cells (T_{SCM}), and microglial cells [5, 14]. These compartments are characterized by self-renewal capacity and longevity, allowing viral persistence independent of viral replication [15].

3.5. Applied Example: Structural Infeasibility Under Access Delays

Comparison of the derived biological windows against empirically observed access delays in high-risk populations (e.g., people who inject drugs) reveals a fundamental mismatch. Surveillance data indicates that while 85% of sexual exposure cases present to Emergency Departments within 72 hours, structural delays for injection-related exposures consistently exceed the compressed 24-hour parenteral window [16, 17].

For this population, the cycle time required to navigate arrest, withdrawal, and housing instability (T_{struct}) almost invariably exceeds the biological cycle time (T_{bio}). Consequently, the condition $R_0(e) = 0$ is biologically unreachable before access is even attempted. In these scenarios, failure is not a probabilistic outcome of drug efficacy or adherence, but a deterministic result of timing constraints.

7

4. Discussion

4.1. Theoretical Implications

Prevention is fundamentally an existence problem: does a state $R_0(e) = 0$ exist and is it reachable? Our analysis shows that PEP failure often represents a boundary violation rather than adherence failure; late intervention cannot alter the initial condition $R(0) > 0$ once it has been established [9].

4.2. Biological Proof of Concept: CCR5-$\Delta 32$

The only known "cure" scenarios involve CCR5-$\Delta 32$ transplantation, which effectively eliminates the susceptibility term in the transmission equation [13]:

$$\frac{dR}{dt} = \lambda SV \cdot 0 = 0 \tag{6}$$

This intervention functions as a system replacement rather than a reversal of the infection state, reinforcing the irreversibility of the integrated provirus in susceptible hosts.

4.3. Implications for Epidemic Control

Reactive interventions cannot achieve epidemic control when biological establishment precedes access. Prevention architectures must therefore be evaluated against biological feasibility constraints, not solely pharmacological efficacy [18].

5. Future Work

Future analyses will explore stochastic population dynamics and network-level avoidance collapse resulting from these constraints. The specific impact of architectural failure on population-level incidence is explicitly deferred to subsequent analysis.

References

[1] R. M. Grant, J. R. Lama, P. L. Anderson, V. McMahan, A. Y. Liu, L. Vargas, et al., Preexposure chemoprophylaxis for HIV prevention in men who have sex with men, New England Journal of Medicine 363 (27) (2010) 2587–2599. `doi:10.1056/NEJMoa1011205`.

[2] P. L. Anderson, D. V. Glidden, A. Liu, S. Buchbinder, J. R. Lama, J. V. Guanira, et al., Emtricitabine–tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men, Science Translational Medicine 4 (151) (2012) 151ra125. `doi:10.1126/scitranslmed.3003707`.

[3] S. M. Blower, H. Dowlatabadi, Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model as an example, International Statistical Review 62 (2) (1994) 229–243. `doi:10.2307/1403510`.

[4] A. J. McMichael, S. L. Rowland-Jones, The immune response to HIV, Immunity 33 (4) (2010) 431–441. `doi:10.1016/j.immuni.2010.08.006`.

[5] A. Wahl, L. Al-Harthi, HIV infection of non-classical cells in the brain, Retrovirology 20 (1) (2023) 1. `doi:10.1186/s12977-023-00616-9`.

[6] J. D. Siliciano, R. F. Siliciano, Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells capable of producing infectious HIV-1, Methods in Molecular Biology 1354 (2015) 3–15. `doi:10.1007/978-1-4939-3067-2_1`.

[7] D. Greenhalgh, G. Hay, Mathematical modelling of the spread of HIV/AIDS amongst injecting drug users, IMA Journal of Mathematics Applied in Medicine and Biology 14 (1) (1997) 11–38.

[8] Y. Liang, D. Greenhalgh, X. Mao, A Stochastic Differential Equation Model for the Spread of HIV amongst People Who Inject Drugs, Computational and Mathematical Methods in Medicine 2016 (2016) 1–14. `doi:10.1155/2016/6757928`.

[9] I. Grant, J. H. Atkinson, J. R. Hesselink, C. J. Kennedy, D. D. Richman, S. A. Spector, J. A. McCutchan, Evidence for Early Central Nervous System Involvement in the Acquired Immunodeficiency Syndrome (AIDS) and Other Human Immunodeficiency Virus (HIV) Infections, Annals of Internal Medicine 107 (6) (1987) 828–836. `doi:10.7326/0003-4819-107-6-828`.

[10] M. R. Tanner, J. G. O'Shea, K. M. Byrd, M. Johnston, G. G. Dumitru, J. N. Le, A. Lale, K. K. Byrd, P. Cholli, E. Kamitani, W. Zhu, K. W. Hoover, A. P. Kourtis, Antiretrovi-

ral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV – CDC recommendations, United States, 2025, MMWR Recomm Rep 74 (1) (2025) 1–56. `doi:10.15585/mmwr.rr7401a1`.

[11] S. A. Strathdee, I. Kuo, N. El-Bassel, S. Hodder, L. R. Smith, S. A. Springer, Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus c'est la même chose, AIDS 34 (14) (2020) 1997–2005. `doi:10.1097/QAD.0000000000002673`.

[12] T. R. Brown, A. Castillejo, Long-term follow-up of the London patient—the second adult to be cured of HIV-1 infection, Lancet HIV 6 (12) (2019) e821–e829. `doi:10.1016/S2352-3018(19)30408-3`.

[13] G. Hutter, D. Nowak, M. Mossner, S. Ganepola, A. Müßig, B. Winter, et al., Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell-derived grafted dendritic cells, New England Journal of Medicine 360 (7) (2009) 692–698. `doi:10.1056/NEJMoa0802905`.

[14] A. M. Anderson, L. Munro, B. Phipps, S. Spudich, V. Valcour, S. Nightingale, Neuroinflammation in HIV: The role of translocator protein, Journal of Neurovirology 26 (6) (2020) 768–786. `doi:10.1007/s13365-020-00882-9`.

[15] J. Hellmuth, J. L. Fletcher, V. Valcour, S. Spudich, A. M. Anderson, M. Vinikoor, et al., Very early initiation of antiretroviral therapy during acute HIV infection is associated with normalized levels of immune activation markers in cerebrospinal fluid but not in plasma, Journal of Infectious Diseases 220 (2) (2018) 208–213. `doi:10.1093/infdis/jiy348`.

[16] J. L. Taylor, A. Y. Walley, A. R. Bazzi, Stuck in the window with you: HIV exposure prophylaxis in the highest risk people who inject drugs, Substance Abuse 40 (4) (2019) 441–443. `doi:10.1080/08897077.2019.1635551`.

[17] A. R. Baugher, C. Wejnert, D. Kanny, D. Broz, J. Feelemyer, R. B. Hershow, et al., Are we ending the HIV epidemic among persons who inject drugs? Key findings from 19 US cities, AIDS 39 (12) (2025) 1813–1819. `doi:10.1097/QAD.0000000000004249`.

[18] F. J. J. Palella, K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrman, G. A. Satten, et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, New England Journal of Medicine 338 (13) (1998) 853–860. `doi:10.1056/NEJM199803261381301`.

Data Sharing

All model code, simulation outputs, and analysis scripts are available at `https://github.com/Nyx-Dynamics/Prevention-Theorem`. All model inputs derive from published literature or synthetic populations; no individual-level data were used.

Declaration of Interests

The author reports prior employment with Gilead Sciences, Inc. from January 2020 through November 2024 and prior ownership of company stock, which was fully divested in December 2024. Gilead Sciences, Inc. had no role in the conception, design, analysis, interpretation, or writing of this study, and provided no funding, data, materials, or input into any aspect of the work.

The author is the owner of Nyx Dynamics, LLC, a consulting company providing advisory and fractional leadership services in healthcare, technology, and complex systems. This research was conducted independently, released as open-source work, and was not produced as part of, or in support of, any paid consulting engagement.

No other competing interests are declared.

Ethics Approval and Consent to Participate

This study did not involve human participants, human biological samples, or the collection of identifiable private information. All analyses were conducted using publicly available, aggregate data from published literature and guidelines. As such, institutional review board (IRB) approval and informed consent were not required.

Acknowledgments